Assets and liabilities of drug repositioning

Rupam Gill, V. Amberkar Mohan Babu*, K. Meena Kumari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Drug discovery is an awfully tenacious job that takes an enormous amount of time, resources, and money, yet yields unsubstantial results. Drug repositioning is a method for "discovering new uses for old drugs." The main objective to repurpose a drug is to extend the application line of an existing drug, thereby narrowing the productivity gap and at the same time allows a swift reach to the market with high chances of revenues. This approach aims at new formulations, dosage, drug combination, delivery system, alternative pathways and targets, orphan diseases. Likewise the de novo drug development, drug repositioning also shares many pros and cons. At one hand, drug repositioning offers relatively less riskversus- reward ratio; on the other hand, the regulatory authority approval process, intellectual property rights and out-licensing are issues of concern. This review article will particularly focus on the various pros and cons associated with drug repositioning.

Original languageEnglish
Pages (from-to)P47-P53
JournalInternational Journal of Pharma and Bio Sciences
Volume7
Issue number4
DOIs
Publication statusPublished - 01-01-2016

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Assets and liabilities of drug repositioning'. Together they form a unique fingerprint.

Cite this